Pfizer Makes Its M&A Move; Hospira Will Be More Of A Bolt-On, Read Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer will buy the sterile-injectables specialist Hospira for $17 billion including debt, marking its first large-scale M&A since the company failed in its bid to buy AstraZeneca last year. The deal will expand Pfizer’s Global Established Pharmaceutical business and bolster its biosimilar portfolio.